EUVIMEDEUVIMED entdecken
Open Access · CC0

Therapeutic efficacy of artemether-lumefantrine plus single low dose primaquine for the treatment of uncomplicated Plasmodium falciparum malaria in a high transmission setting, Western Ethiopia

Jimma Dinsa Deressa iD, Sinknesh Wolde Behaksra, Eshetu Molla, Alemayehu Letebo, Girma Shumie, Bethlehem Adnew, Dawit Hailu Alemayehu, Fikregabrail Aberra Kassa, Tamrayehu Seyoum, Elias B Tafa iD, Kidist Woldekidan, Legesse Alamerie Ejigu und 8 weitere

PLOS One · 17.07.2026 · 21 (7) · e0335833

DOI: 10.1371/journal.pone.0335833 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 17.07.2026. Verfasst von Jimma Dinsa Deressa und 19 weiteren Autor:innen. Beteiligte Einrichtung: Armauer Hansen Research Institute, Malaria and Neglected Tropical Diseases Research Division, Addis Ababa, Ethiopia. Hauptthemen laut MEDLINE: Primaquine, Artemether, Lumefantrine Drug Combination, Malaria, Falciparum, Antimalarials. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Armauer Hansen Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The development and spread of drug-resistant parasites continue to threaten progress toward malaria elimination. Therapeutic efficacy and molecular resistance marker studies are needed to guide national control programs. In African settings, evidence of partial resistance to artemisinin-based combination therapies (ACTs) associated with Pfkelch13 mutations is accumulating, and World Health Organization (WHO) recommends regular monitoring of first line antimalarial drugs for early detection of resistant parasites. In this study, we evaluated the efficacy of artemether-lumefantrine (AL) combined with a single low dose of primaquine (PQ) for treating uncomplicated Plasmodium falciparum malaria in a co-endemic area where P. falciparum predominates. Methods and findings One hundred twenty-three patients with P. falciparum mono-infection were enrolled between November 2020 to March 2021 and treated with artemether-lumefantrine (AL) plus a single low dose of primaquine (PQ) as per the national malaria treatment guideline and followed up for 28 days. Ethical approval was obtained from the AHRI/ALERT ethics committee (Po/23/19), and the study was registered at Pan-African clinical trials registry (PACTR) with unique identification number of PACTR202509595696440. Pfmsp2 capillary electrophoresis (CE) genotyping was used to differentiate recrudescence from new infections. More than half (56.1%) of the participants had high parasitemia (>10,000 parasites/μL) at enrollment. On day 3, 16.9% (20/118) remained parasitemic, and of the 10 individuals with detectable gametocytes at enrollment, only 3.4% remained gametocytemic on day 3, and 100% parasite clearance was observed on day 7, respectively. Multiplicity of infection was 3.8 at enrollment and 1.7 at the time of recurrence. The adequate clinical and parasitological responses at 28-day (ACPR) of per protocol analysis (PPA) was 73.7% for PCR-uncorrected and 91.3% for PCR-corrected, respectively and while, the intention-to-treat analysis (ITA), the Kaplan–Meier estimated treatment success at day 28 was 93.2% (95% CI: 88.5–98.2) after PCR correction, compared with 78.3% (95% CI: 71.0–86.4) in the PCR-uncorrected analysis. In our study assessment, no cases of severe malaria or serious adverse events occurred.

Conclusions

The efficacy observed in this study, although remaining above the WHO policy change threshold after PCR correction, may indicate a potential decline in AL’s effectiveness in this high transmission setting. However, because antimalarial drug concentrations were not measured and evening doses were not fully directly observed, reduced drug exposure or imperfect adherence cannot be excluded as possible contributors to the observed treatment outcomes Therefore, we suggest regular therapeutic efficacy monitoring and further investigation using advanced molecular techniques, such as next-generation sequencing (NGS), to enable early detection of resistance-associated parasite variants that may compromise treatment efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrimaquineArtemether, Lumefantrine Drug CombinationMalaria, FalciparumAntimalarialsHumansFemaleMaleEthiopiaPlasmodium falciparumChild, PreschoolAdolescentTreatment OutcomeChildAdultDrug Therapy, CombinationYoung Adult

Substanzen

PrimaquineArtemether, Lumefantrine Drug CombinationAntimalarials

Autor:innen und Institutionen

  • Armauer Hansen Research Institute, Malaria and Neglected Tropical Diseases Research Division, Addis Ababa, Ethiopia.
  • Department of Applied Biology, School of Applied Natural Science, Adama Science and Technology University, Adama, Ethiopia.
  • Addis Ababa University, Addis Ababa, Ethiopia.
  • Department of Biological Science, University of Notre Dame, Notre Dame, United States of America.
  • Ministry of Health, Malaria elimination program, Addis Ababa, Ethiopia.

ORCID-Profile: Jimma Dinsa Deressa, Elias B Tafa

Förderung

  • Armauer Hansen Research Institute

Zitieren

APA

Deressa, J. D., Behaksra, S. W., Molla, E., Letebo, A., Shumie, G., Adnew, B., Alemayehu, D. H., Kassa, F. A., Seyoum, T., Tafa, E. B., Woldekidan, K., Ejigu, L. A., Huwe, T., Keffale, M., Bayissa, G. A., Koepfli, C., Chala, B., Asmamaw, Y., Tadesse, F. G., & Gadisa, E. (2026). Therapeutic efficacy of artemether-lumefantrine plus single low dose primaquine for the treatment of uncomplicated Plasmodium falciparum malaria in a high transmission setting, Western Ethiopia. PLOS One, 21(7), e0335833. https://doi.org/10.1371/journal.pone.0335833

Vancouver

Deressa JD, Behaksra SW, Molla E, Letebo A, Shumie G, Adnew B, et al. Therapeutic efficacy of artemether-lumefantrine plus single low dose primaquine for the treatment of uncomplicated Plasmodium falciparum malaria in a high transmission setting, Western Ethiopia. PLOS One. 2026;21(7):e0335833. doi:10.1371/journal.pone.0335833

BibTeX
@article{Deressa2026,
  author = {Deressa, Jimma Dinsa and Behaksra, Sinknesh Wolde and Molla, Eshetu and Letebo, Alemayehu and Shumie, Girma and Adnew, Bethlehem and Alemayehu, Dawit Hailu and Kassa, Fikregabrail Aberra and Seyoum, Tamrayehu and Tafa, Elias B and Woldekidan, Kidist and Ejigu, Legesse Alamerie and Huwe, Tiffany and Keffale, Migbaru and Bayissa, Gudissa Assefa and Koepfli, Cristian and Chala, Bayissa and Asmamaw, Yehenew and Tadesse, Fitsum Girma and Gadisa, Endalamaw},
  title = {Therapeutic efficacy of artemether-lumefantrine plus single low dose primaquine for the treatment of uncomplicated Plasmodium falciparum malaria in a high transmission setting, Western Ethiopia},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {7},
  pages = {e0335833},
  doi = {10.1371/journal.pone.0335833}
}
Kostenlos starten →